AVRO News and Press, AVROBIO Inc. From 11/07/19

AVROBIO (NASDAQ: AVRO ): Q3 GAAP EPS of -$0.57 beats by $0.02 . More news on: AVROBIO, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Dosing of first Fabry patient incorporating plato™ anticipated for fourth quarter 2019 All Fabry patients who discontinued enzyme replacement therapy (ERT) following treatment with AVR-RD-01 investigational gene therapy remain off ERT FDA orphan drug designation granted for...

AVROBIO, Inc . (NASDAQ: AVRO) (the “Company”), today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for the Company’s investigational gene therapy, AVR-RD-02, for the treatment of Gaucher disease. AVR-RD-02 consists of the ...

Company developing commercial strategies and operational capabilities to support future product launches as investigational gene therapies advance through clinic Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) AVROBIO, Inc . (NASDAQ: AVRO) (the “...

The first patient has been dosed in AVROBIO's (NASDAQ: AVRO ) Phase 1/2 clinical trial of AVR-RD-04 investigational gene therapy program for cystinosis, a devastating lysosomal storage disease. More news on: AVROBIO, Inc., Healthcare stocks news, Read more ...

Investigational Therapy Designed to Engineer Patients’ Own Stem Cells to Produce Essential Protein AVROBIO, Inc . (NASDAQ: AVRO) (the “Company”) today announced that the first patient has been dosed in the Company’s AVR-RD-04 investigational gene therapy ...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stoc...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

AVROBIO, Inc . (NASDAQ:AVRO), a Phase 2 clinical-stage gene therapy company, today announced that Geoff MacKay, President and CEO of AVROBIO, will present at Chardan’s 3 rd Annual Genetic Medicines Conference on Monday, October 7, 2019. Chardan's 3 rd Annual Genetic Medicines C...

The following slide deck was published by AVROBIO, Inc. in conjunction with this Read more ...